IAP15 Rec'd PCT/PTO 13 JUN 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES	43072-0002US1							
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/559,157							
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
TITLE OF INVENTION DRUG CANDIDATE SELECTION BY HYDROGEN EXCHANGE CHARACTERIZATION OF LIGAND-INDUCED RECEPTOR								
CONFORMATION APPLICANT(S) FOR DO/EO/US Mark Robert Southern; Yoshitomo Hamuro; Patrick Robert Griffin								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO	O/US) the following items and other information:							
1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371								
2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.								
3. This is an express request to begin national examination procedures (35 U.S.C. 37 (5), (6), (9) and (21) indicated below.								
4. The US has been elected (Article 31).								
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
a. is attached hereto (required only if not communicated by the Internation	nal Bureau).							
b. has been communicated by the International Bureau.								
c. is not required, as the application was filed in the United States Receivi	ng Office (RO/US).							
6. An English language translation of the International Application as filed (35 U.S.C	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
a. Lis attached hereto.								
b. has been previously submitted under 35 U.S.C. 154(d)(4).								
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
a. are attached hereto (required only if not communicated by the Internat	tional Bureau).							
b. have been communicated by the International Bureau.								
c. have not been made; however, the time limit for making such amendm	nents has NOT expired.							
d. have not been made and will not be made.								
8. An English language translation of the amendments to the claims under PCT Art	icle 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10. An English language translation of the annexes of the International Preliminary E Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 20 below concern document(s) or information included:								
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
12. An assignment document for recording. A separate cover sheet in compliance with	th 37 CFR 3.28 and 3.31 is included.							
13. A preliminary amendment.	A preliminary amendment.							
14. An Application Data Sheet under 37 CFR 1.76.	An Application Data Sheet under 37 CFR 1.76.							
15. A substitute specification.	A substitute specification.							
16. A power of attorney and/or change of address letter.								
17. A computer-readable form of the sequence listing in accordance with PCT Rule 1	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.							
18. A second copy of the published International Application under 35 U.S.C. 154(d)(A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
his collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to	obtain or retain a benefit by the public, which is to file (and by the							

Inis collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL Mailing Label Number: CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

Date of Deposit: 6/13/16

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, EXPRESS MAIL. POST OFFICE TO ADDRESSET service under 31 C.F.R. 1.10, on the date indicated above, and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Signature of person major pages: Hama

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. 10/559, 157 PCT/US2004/021472				ATTORNEY'S DOCKET NUMBER 43072-0002US1				
20. Other items or information:								
The fell	owing fees have b	oon submitted			CALCULATIONS	PTO USE ONLY		
	-		••••••	\$300	\$	FIO USE ONLY		
				-				
22. Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 All other situations\$200					\$			
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority					\$			
	TOTAL OF 21, 22	2 and 23 =						
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets		additional 50 or fraction up to a whole number)	RATE				
- 100 =	/50 =			x \$250	\$	l		
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).					\$			
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$			
Total claims		- 20 =		x \$50				
Independent clai	ms	- 3 =		x \$200	\$			
MULTIPLE DEP	ENDENT CLAIM(S	(if applicable)		+ \$360	\$			
	TOTAL OF ABOVE CALCULATIONS =							
Applicant cla	ims small entity st	atus. See 37 CF	R 1.27. Fees above are reduc	· · · · · · · · · · · · · · · · · · ·		` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `		
SUBTOTAL =			\$					
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).			\$					
TOTAL NATIONAL FEE =			\$	**				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$					
TOTAL FEES ENCLOSED =				\$				
				Amount to be refunded:	\$			
				Amount to be charged	\$			

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

а. 🔲	A check in the amount of \$ to cover the abo	ve fees is enclosed.						
ь. 🗆	Please charge my Deposit Account No in the amount of \$ A duplicate copy of this sheet is enclosed.	to cover the above fees.						
c. X	c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0573. A duplicate copy of this sheet is enclosed.							
d. 🔲	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND A	ALL CORRESPONDENCE TO:	July -						
Dani	el A. Monaco	SIGNATURE						
Drin	ker Biddle & Reath LLP	Daniel A. Monaco						
One :	Logan Square	NAME						
18th	and Cherry Streets	30,480						
Phil	adelphia, PA 19103	REGISTRATION NUMBER						

ATTORNEY DOCKET No.: 43072-0002US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Mark Robert Southern, et al.

Application No: 10/559,157

(International Application No: PCT/US2004/021472)

Filed:

(International Application: 02 July 2004 (02.07.2004))

For:

DRUG CANDIDATE SELECTION BY HYDROGEN EXCHANGE

CHARACTERIZATION OF LIGAND-INDUCED RECEPTOR

CONFORMATION

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The present application is a 35 U.S.C. § 371 of PCT/US2004/021472. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate as a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. A copy of the International Search Report is enclosed.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EVユ98789389以

Date of Deposit: 6/13/06

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of person mailing page:

Type or print name of person

INFORMATION DISCLOSURE STATEMENT US NATL. PHASE OF PCT/US2004/021472

ATTORNEY DOCKET No. 43072-0002US1

The Examiner is respectfully requested to review the items listed on the substitute PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or prior art, or that more relevant references do not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

MARK ROBERT SOUTHERN, et al.

BY_

DANIEL A. MONACO Registration No. 30,480 DRINKER BIDDLE & REATH LLP One Logan Square 18th and Cherry Streets Philadelphia, PA 19103-6996

TEL: (215) 988-3312 FAX: (215) 988-2757 Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERC PATENT AND TRADEMARK OFFICE					in in the content in				SERIAL NO. 10/559,157 (I.A. PCT/US2004/021472)			
INFORMATION DISCLOSURE STATEMENT				IENT	APPLICANT: Mark Robert Southern, et al.							
					FILING DATE (I.A. July 2, 2004)				GROUP Not Yet Assigned			
			U.S.	PATENT DOC	UMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME			SUBCLASS		ss	FILING DATE (IF APPROPRIATE)	
	AA	5,989,827	11/23/99	Fesik et al.	* * *******************************	435	5 7.1				-	
	AB	2004/0153256	8/5/04	Woods, Jr.			702	2 27		10/17/03		
 								-				
								+				
								-				
								-				
	l		FOREIC	ON PATENT DO	OCUMENT	`S		L		i		
		DOCUMENT NO. DATE COUNTRY CLASS SUBCL				BCL	TRANSLATION ASS					
									YES		·	NO T
						ļ <u> </u>						
				-	-	 						
			 									
						<u> </u>						-
		OTHER DOC	LIMENTS (I	cluding Author,	Title Date	Portino	nt Pages	Etc)		<u>.</u>	
	AC	Smith, et al. "Pro						-		Excl	nange and M	ass
<u> </u>		Spectrometry", Jo										
AD Marinissen, et al. "A Network of Mitogen-Activated Protein Kinases Links G Protein-Coupled Receptors to the c-jun Promoter: a Role for c-Jun NH ₂ -Terminal Kinase, p38s, and Extracellular Signal-Regulated Kinase 5", Molecular and Cellular Biology, June 1999, p. 4289-4301.												
	AE Shiau, et al. "The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen", Cell, Vol. 95, 927-937, December 23, 1998.							m of				
										-	· · · · · · · · · · · · · · · · · · ·	
EXAMINE	R			D	ATE CONS	IDERE	D .					
		citation considered, whe					v line thro	ugh ci	tation			